VivekSubbiahMD

Oncology • Nashville, TN

Endocrine Cancer, Hematologic Oncology, Sarcoma

Chief, Early-Phase Drug Development, SCRI

Join to view full profile

Dr. Subbiah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Subbiah's full profile

Already have an account?

Office
335 24th Ave N #200
Nashville, TN 37203
Phone+1 615-329-7640

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2012
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Pediatric Hematology/Oncology, 2008 - 2011
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine/Pediatrics, 2004 - 2008
Sri Ramachandra Medical CollegeClass of 2002

Certifications & Licensure

FL State Medical License 2021 - Present
TN State Medical License 2023 - 2026
TX State Medical License 2010 - 2025
OK State Medical License 2020 - 2021
OH State Medical License 2004 - 2009
American Board of Internal Medicine Medical Oncology

Clinical Trials

Trial of Curcumin in Advanced Pancreatic Cancer Start of enrollment: 2004 Nov 01
Completed
Phase 2
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer Start of enrollment: 2012 May 14
Active, not recruiting
Phase 1
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer Start of enrollment: 2012 Dec 18
Completed
Phase 1
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma Start of enrollment: 2013 Oct 16
Completed
Phase 1, Phase 2
Safety and Efficacy Study of DCVax-Direct in Solid Tumors Start of enrollment: 2013 Jun 01
Unknown status
Phase 1, Phase 2
BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors Start of enrollment: 2013 Oct 01
Completed
Phase 1
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Regorafenib and Cetuximab in Patients With Advanced Malignancy Start of enrollment: 2014 Mar 19
Completed
Phase 1
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) Start of enrollment: 2014 Sep 17
Terminated
Phase 2
LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE) Start of enrollment: 2014 Aug 25
Completed
Phase 2
Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers Start of enrollment: 2018 Mar 12
Completed
Phase 1
Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors Start of enrollment: 2018 Mar 12
Completed
Phase 1
A Study of LY3405105 in Participants With Advanced Cancer Start of enrollment: 2019 Jan 31
Terminated
Phase 1
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study Start of enrollment: 2019 Dec 14
Active, not recruiting
Phase 2
The Registry of Oncology Outcomes Associated With Testing and Treatment Start of enrollment: 2021 May 05
Recruiting
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 01
Recruiting
Phase 1, Phase 2
TCF-001 TRACK (Target Rare Cancer Knowledge) Study Start of enrollment: 2020 Oct 01
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.
Manuel Dómine Gómez, Vivek Subbiah, Solange Peters, María Angeles Sala, José Trigo
Expert Review of Anticancer Therapy. 2024-12-12
Leptomeningeal metastatic disease: new frontiers and future directions.
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz
Nature Reviews. Clinical Oncology. 2024-12-09
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma.
Sarah Hamidi, Sireesha Yedururi, Mimi I Hu, Naifa L Busaidy, Steven I Sherman
Thyroid. 2024-12-04

Lectures

Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

US FDA Approves Illumina Cancer Biomarker Test, TruSight Oncology with Two CDx to Rapidly Match Patients to Targeted TherapiesAugust 29th, 2024
Identification of Immune Checkpoint Inhibitor–Induced DiabetesAugust 29th, 2024
FDA Approves Illumina Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted TherapiesAugust 27th, 2024
Join now to see all